论文部分内容阅读
目的:观察替米沙坦联合氨氯地平对糖尿病合并高血压患者血糖、血脂的影响。方法:将符合纳入标准的80例门诊糖尿病合并高血压患者随机分为联合治疗组(替米沙坦40 mg联合氨氯地平2.5 mg,均po,qd)40例及单药治疗组(氨氯地平5 mg,po,qd)40例。观察治疗前及治疗16周后患者血压、血脂及血糖变化。结果:联合治疗组治疗后空腹血糖、三酰甘油较前有明显下降,且与单药治疗组比较差异有统计学意义(P<0.05)。联合治疗组治疗后低密度脂蛋白胆固醇较前明显下降,但与单药治疗组相比差异无统计学意义。结论:替米沙坦联合氨氯地平治疗糖尿病合并高血压患者,在降压的同时能改善血糖、血脂水平,有较好的应用前景。
Objective: To observe the effect of telmisartan combined with amlodipine on blood glucose and blood lipid in patients with diabetes complicated with hypertension. Methods: A total of 80 outpatients with diabetes mellitus complicated with hypertension were enrolled in the study. They were randomly divided into the combined treatment group (telmisartan 40 mg combined with amlodipine 2.5 mg, po, qd) and monotherapy Level 5 mg, po, qd) 40 cases. The changes of blood pressure, blood lipid and blood glucose before and 16 weeks after treatment were observed. Results: After treatment, fasting blood glucose and triglyceride in combination therapy group were significantly lower than those in the former group (P <0.05). LDL cholesterol decreased significantly after treatment in combination therapy group, but there was no significant difference compared with monotherapy group. Conclusion: Telmisartan combined with amlodipine in patients with diabetes mellitus and hypertension can reduce blood pressure and improve blood sugar and blood lipid levels, which has a good application prospect.